Skip to main content
World Journal of Diabetes logoLink to World Journal of Diabetes
. 2014 Aug 15;5(4):493–504. doi: 10.4239/wjd.v5.i4.493

Genetic polymorphisms of cytokine genes in type 2 diabetes mellitus

Monisha Banerjee 1, Madhukar Saxena 1
PMCID: PMC4127584  PMID: 25126395

Abstract

Diabetes mellitus is a combined metabolic disorder which includes hyperglycemia, dyslipidemia, stroke and several other complications. Various groups all over the world are relentlessly working out the possible role of a vast number of genes associated with type 2 diabetes (T2DM). Inflammation is an important outcome of any kind of imbalance in the body and is therefore an indicator of several diseases, including T2DM. Various ethnic populations around the world show different levels of variations in single nucleotide polymorphisms (SNPs). The present review was undertaken to explore the association of cytokine gene polymorphisms with T2DM in populations of different ethnicities. This will lead to the understanding of the role of cytokine genes in T2DM risk and development. Association studies of genotypes of SNPs present in cytokine genes will help to identify risk haplotype(s) for disease susceptibility by developing prognostic markers and alter treatment strategies for T2DM and related complications. This will enable individuals at risk to take prior precautionary measures and avoid or delay the onset of the disease. Future challenges will be to understand the genotypic interactions between SNPs in one cytokine gene or several genes at different loci and study their association with T2DM.

Keywords: Type 2 diabetes, Cytokines, Single nucleotide polymorphisms, Disease susceptibility, Association studies


Core tip: Diabetes is the third most widespread disease after heart disease and cancer. Cytokines are mediators of inflammation, namely interleukins (IL)-1β, -1Ra, -18, -4, -6, -10, tumor necrosis factor-α and adiponectin, which cause immune responses in disease pathogenesis, including type 2 diabetes. In the present study, the association of cytokine gene polymorphisms in different ethnic populations is reviewed. Such single nucleotide polymorphism analyses and association studies in different populations will benefit individuals belonging to a particular group.

INTRODUCTION

Type 2 diabetes mellitus (T2DM) is a group of metabolic disorders characterized by high blood sugar levels, which results from defects in insulin secretion or action or both, leading to complications[1]. Diabetes mellitus has now been associated with the development of a long term organ disease. T2DM has changed from a mild disorder of old age to a serious cause of morbidity and mortality in young and middle-aged people. The Diabetes Atlas estimates have shown that 371 million people suffer from diabetes worldwide, with India alone having 63.0 million affected individuals and the number is expected to rise to 101.0 million by 2030[2-4]. This alarming figure has instigated several workers worldwide to undertake genetic studies and contribute to the understanding and early detection of the disease.

A predisposition to T2DM or “Adult Onset Diabetes” is probably inherited as an autosomal recessive trait[5]. T2DM is treated initially by diet control, either alone or in combination with orally administered anti-diabetic drugs. It is described as a syndrome on the basis of clustering of many abnormalities, like resistance to insulin-stimulated glucose uptake, hyperinsulinemia, hyperglycemia, increased very low density lipoprotein (VLDL), increased triglycerides, decreased high density lipoproteins (HDL) cholesterol, high blood pressure, micro albuminuria, hyperuricemia, fibrinolytic and coagulation abnormalities, etc[3].

Evidence has shown that T2DM is associated with chronic inflammation that can be attributed to dysregulation of the innate immune system and this is a potential link between metabolic syndrome, diabetes and atherosclerosis[6]. A large and diverse family of small, low molecular weight cell signaling proteins mediating complex interaction are called “cytokines”, which include interleukins and interferons[7] secreted by white blood cells and various other cells in response to a number of stimuli. The cytokines and their receptors exhibit a very high affinity for each other. Another subgroup of low molecular weight cytokines called chemokines affect leukocyte behavior. Cytokines are of two types, namely pro-inflammatory [e.g., interleukins (IL)-1, -6, tumor necrosis factor (TNF)-α, transforming growth factor (TGF)-β] and anti-inflammatory (e.g., IL-1Ra, -4, -10, -13), which function opposite to each other. The release of adipocytokines by adipocytes, such as leptin, resistin, adiponectin and visfatin, as well as some of the classical inflammatory cytokines like TNF-α, IL-6, MCP-1 (CCL-2) etc., help to achieve this. Studies have shown that it is the fat tissue that exerts the endocrine and immune functions. Macrophages and T cells are found in abundance in adipose tissue which develops into an organized immune organ[8]. Inflammation resulting from an imbalance between pro- and anti-inflammatory cytokines leads to T2DM and its complications (Figure 1).

Figure 1.

Figure 1

A schematic diagram showing the involvement of various cytokines in diabetes[3]. IL: Interleukin; TNF: Tumor necrosis factor.

Mediators of inflammation, such as IL-1β, -1Ra, -18, -4, -6, -10, TNF-α and adiponectin (ADIPOQ), have been proposed to be involved in causing T2DM. Elevated blood levels of certain acute phase markers such as IL-6 can characterize the immune response[9], while IL-1 regulates the basic metabolic rate, blood glucose levels, blood pressure, iron metabolism and bone remodeling. Adiponectin levels and its gene variants have also been confirmed to be associated with increased risk of T2DM[10]. To date, more than 1240 gene loci are associated with diabetes in humans[3]. The susceptibility to complex forms of T2DM is associated with frequent polymorphisms that influence the expression of genes belonging to the same or different causal pathways[7]. It is important to understand the nature and actions of these adipocytokines in order to find their association with diseases like T2DM, atherosclerosis, other metabolic and vascular diseases (Figure 2). Studies have reported that Asian Indians are a unique population for carrying out genetic studies due to their greater susceptibility to T2DM and increased insulin resistance[11,12]. This review is an attempt to put together certain important cytokine gene polymorphisms and their association with T2DM in different populations around the world.

Figure 2.

Figure 2

A schematic diagram showing the metabolic defects and biochemical effects of cytokines leading to type 2 diabetes. T2DM: Type 2 diabetes; IL: Interleukin; TNF: Tumor necrosis factor.

CYTOKINE GENE POLYMORPHISMS AND T2DM

Certain chemokines/cytokines, like IL-1β, -1Ra, -18, -4, -6, -10, TNF-α, etc., and some members of the adipocytokine family, namely adiponectin, leptin and resistin, are important mediators in inflammation/disease and glucose metabolism and may be involved in the pathogenesis of T2DM. They can be used as biological markers for diabetes and are related to obesity and hypertension. The single nucleotide polymorphisms (SNPs) present in the regulatory regions of cytokine genes often have an impact on their expression levels and can be disease modifiers. The degree of inflammation is controlled, thereby leading to the progression of various immunological diseases, including T2DM[13-20]. The polymorphisms in cytokine genes lead to interindividual differences in their production, leading to variations in immune responses[21].

IL-1α, -1β and -Ra

The IL-1 family consists of two pro- and one anti- inflammatory cytokines, namely 1α, 1β and the IL-1 receptor antagonist (IL-1Ra), respectively. While IL-1α and -1β enhance inflammation and host defense, IL-Ra counteracts their function. A variety of cell types like monocytes/macrophages and keratinocytes are known to produce these cytokines. All three secreted glycoproteins bind to IL-1 receptors[22].

The IL-1 genes (IL-1α, -β and -Ra) are located on chromosome 2q12-21. All IL-1 genes are polymorphic and several are associated with inflammation and disease conditions[7,23]. “Autocrine apoptosis” results from prolonged exposure of human islets to high glucose which triggers IL-1β production, leading to activation of nuclear factors and upregulation of Fas signaling[24]. IL-1β and IL-1Ra play important roles in tissue remodeling, are potent mediators of chronic inflammation[25] and are therefore implicated in the pathogenesis of T2DM and associated complications[7]. The IL-1 gene variants studied in various groups are shown in Table 1.

Table 1.

Variants of interleukin-1 gene cluster (interleukin-1α, interleukin-1β, interleukin-1Ra, interleukin-18) and their association with type 2 diabetes in different populations

Gene Variants (SNPs) Population-Ethnic group Association Ref.
IL-1α -889 NS [26]
IL-1β 3954
IL-1β -511
IL-1Ra VNTR
IL-1α 3'UTR Caucasians and African Americans S [27]
IL-1 C-889T East Indian S [28]
IL-1β C-511T
IL-1β C3953T
IL-1α S [29]
IL-Ra VNTR
IL-1β C3954T S [30]
IL-1β -511 North Indian S [31]
IL-1Ra VNTR
IL-1β C-511T S [32]
IL-1Ra VNTR
IL-1β C-511T Korean S [33]
IL-1Ra VNTR
IL-1Ra VNTR NS [29]
IL-1Ra VNTR S [34]
IL-1Ra VNTR North Indian S [17]
IL-1Ra VNTR Caucasians NS [35]
IL-1Ra VNTR S [36]
IL-1RI PstI, HinfI, AluI (promoter region) Dalmatian population of South Croatia S [37]
PstI (exon 1B region)
IL-18 +183 A/G Norwegian S [38]
-137 G/C NS
-607 C/A NS
-607 C/A Chinese S [39]
BCO2 European S [40]
rs2250417 European NS [41]
5 SNPs European S [42]

UTR: Untranslated region; VNTR: Variable number of tandem repeats; S: Significant; NS: Nonsignificant; IL-1: Interleukin-1; SNPs: Single nucleotide polymorphisms.

IL-18

IL-18, a unique IL-1 family cytokine is expressed in macrophages, keratinocytes, osteoblasts, synovial fibroblasts, dendritic, Kupffer, adrenal cortex, intestinal epithelial and microglial cells[43-50]. IL-18 shares structural homology with IL-1β. It is produced as a 24-kDa inactive precursor, Pro-IL-18, which is cleaved by IL-1β-converting enzyme (ICE; caspase-1) to a mature 18-kDa molecule[51]. The extracellular binding of IL-18 is mediated by IL-18R, a heterodimer complex containing α chain (IL-1Rrp) and β chain (AcPL)[52-54].

Insulin-producing islet β-cells secrete IL-18 and induce IFNγ in T cells[55]. IL-18 is highly expressed in atherosclerotic plaques with a role in plaque destabilization[56]. Elevated levels of plasma IL-18 were reported in T2DM patients and children[57-59]. However, obesity and insulin resistance showed no correlation with IL-18 plasma level[60]. The IL-18 gene in humans is located on chromosome 11q22.2-22.3, where a diabetes susceptibility locus, Idd2, resides[61]. Studies reporting IL-18 gene polymorphisms are shown in Table 1.

IL-4

One of the hematopoietic cytokines, IL-4 regulates key events during Th2-dominated immune response and also stimulates T cells, leading to the production of other cytokines. It causes β-cell isotype switching from IgM to IgE and stimulates IgE production in allergic sensitization. IgE stimulation during allergic reactions and infections is the natural defense mechanism. It also plays a crucial role in the pathophysiology of T2DM[62]. The heterodimerization of high-affinity transmembrane receptor α-chain (IL-4Rα) is mediated by IL-4 in a sequential cascade. Several candidate genes have been identified, including the gene for IL-4Ra which is situated on chromosome 16p and is known to contain a number of polymorphisms. IL-1Ra and IL-4 are major anti-inflammatory cytokines[63] and have been proposed to be involved in events causing T2DM. The IL-4Ra subunit forms part of the signalling complex for IL-4. In humans, the gene for IL-4 maps to chromosome 5q31. The polymorphisms in IL-4 gene and their relationship with T2DM have been studied by various groups (Table 2).

Table 2.

Variants of interleukin-4 gene and their association with type 2 diabetes in different populations

Gene variants (SNPs) Disease Population-Ethnic groups Association Ref.
-590 C/T T2DM Iranian S [64]
-589 C/T T2DM Chinese S [65]
-34 C/T T2DM
VNTR T2DM North Indian S [17]

VNTR: Variable number of tandem repeats; S: Significant; T2DM: Type 2 diabetes; SNPs: Single nucleotide polymorphisms.

IL-6

IL-6 is secreted by immune cells, adipose tissue and muscles and is able to accelerate or inhibit the inflammatory processes[66,67]. The direct affect of IL-6 may be on glucose homeostasis and metabolism or it might act indirectly by action on adipocytes, pancreatic β-cells, etc[68]. In humans, the gene for IL-6 maps to chromosome 7p15-p21. IL-6 mRNA expression and insulin resistance were found to have a significant correlation[69] and increased plasma IL-6 levels with higher risk of T2DM[6,70,71], making it an appealing candidate gene. One of the common polymorphisms in the IL-6 gene promoter (C-174G) was found to regulate transcription in response to inflammatory stimuli, such as lipopolysaccharides or IL-1[72-74]. IL-6 promoter SNPs were considered as risk factors for T2DM development, as reported by other groups[75,76] (Table 3).

Table 3.

Variants of Interleukin-6 gene and their association with type 2 diabetes and related complications in different populations

Gene variants (SNPs) Diseases Population- Ethnic groups Association Ref.
-174 G/C T2DM and OGTT Brazilian S [77]
T2DM and IR American S [78]
T2DM and obesity Polish S [79]
T2DM and obesity Mexican NS [80]
T2DM Indian S [81]
T2DM Finnish NS [82]
T2DM and Obesity Tunisian S [83]
T2DM Caucasian S [84]
T2DM German S [85]
DM, micro-, macrovascular complications Australian NS [29]
-do- German NS [86]
T2DM and IR Italian S [87]
T2DM KORA Survey S [88]
T2DM Framingham Heart Study S [89]
T2DM KORA Survey S [90]
T2DM Taiwanese S [91]
T2DM Nutrition-Potsdam cohort S [92]
T2DM Finnish S [93]
T2DM Native Americans, Spanish, Caucasians S [75]
T2DM and IR Spanish S [94]
T2DM and PAD Italian S [95]
T2DM KORA Survey S [76]
DM and Periodontitis Chinese S [96]
T2DM and Endothelial Dysfunction Chinese S [97]
T2DM 21 studies S [71]
-174 G/C -597 A/G T2DM Boston NS [98]
GWS (18 SNPs) T2DM Canadian S with Fasting [99]
PREDIAN study DN Spanish S [100]
Five tagging SNPs T2DM and Impaired Renal Function Singaporean S [101]

S: Significant; NS: Non-significant; T2DM: Type 2 diabetes; PAD: Peripheral arterial disease; SNPs: Single nucleotide polymorphisms; OGTT: Oral glucose tolerance test; DM: Diabetes mellitus; IR: Insulin resistance; DN: Diabetic nephropathy.

IL-10

IL-10 is also a Th2 mediated cytokine that downregulates inflammatory responses of pro-inflammatory cytokines[102]. The serum concentrations of TC, LDL, TGL, glucose and HbA1c gradually decreases and HDL increases with an increase in IL-10 production. These observations implied that low IL-10 production was associated with hyperglycemia and T2DM[68,103]. IL-10 promotes the proliferation and differentiation of B-lymphocytes by stimulating antibody production[104]. The IL-10 gene is located on chromosome 1q31-q32 and several variants have been identified in its promoter region[105-106]. The presence of IL-10 is protective against T2DM and inflammation due to its humoral immunity responses and prevention of pancreatic beta cell destruction[4,107]. The association of IL-10 gene polymorphisms is shown in Table 4.

Table 4.

Variants of interleukin-10 gene and their association with type 2 diabetes and related complications in different populations

Gene variants (SNPs) Diseases Population- Ethnic groups Association Ref.
-592 A/C T2DM Iranian NS [108]
T2DM Chinese NS [109]
T2DM North Indian S [4]
-1082 G/A proliferative diabetic retinopathy Indian S [110]
T2DM South Indian S [111]
-1082 G/A -819 C/T -592 C/A T2DM Caucasian Italian S [112]
-1082 G/A T2DM Turkish NS [113]
-1082 G/A -819 C/T -592 C/A T2DM Greek NS [106]
-592 A/C -819 C/T T2DM Taiwanese NS [107]
-592 A/C T2DM Taiwanese S [114]
-1087 G/A -824 C/T -597 C/A T2DM Italian S [115]
-592 A/C T2DM Tunisian S [18]

S: Significant; NS: Non-significant; T2DM: Type 2 diabetes; SNPs: Single nucleotide polymorphisms.

TNF-α

TNF-α is released by monocytes/macrophages and has an initial role in β-cell damage of the islets. It is reported that TNF-α is a possible mediator of insulin resistance and diabetes since it decreases the tyrosine kinase activity[116]. Furthermore, TNF-α inhibits insulin signaling[117] and impairs its secretion[118]. TNF-α interacts with IL-6, regulating its expression and downregulating itself[73]. In humans, the gene for TNF-α maps to chromosome 6p21. 3. One of the SNPs in TNF-α gene showed a two-fold increase in transcriptional activity[119,120]. Various groups showed an association of TNF-α SNPs with T2DM (Table 5).

Table 5.

Variants of tumor necrosis factor-α gene and their association with type 2 diabetes and related complications in different populations

Gene variation (SNPs) Diseases Population- Ethnic groups Association Ref.
G-308A T2DM Tarragona S [120]
T2DM Taiwanese S [121]
T2DM Croatian Caucasians S [122]
T2DM and peridontitis Chinese S [123]
T2DM, MS and Obesity Indian S [124]
T2DM Mexican S [125]
Glucose metabolism Brazilian S [126]
T2DM Japanese NS [127]
T2DM Mexican NS [128]
T2DM Chinese NS [129]
T2DM Greek NS [130]
atherosclerotic diabetic Hungarian S [131]
T2DM Indian S [81]
T2DM United Kingdom/Irish NS [132]
T2DM Finnish S [82]
sTNFR1 and sTNFR2 Glucose metabolism Hungarian NS [133]
C-857T IR and T2DM Japanese S [134]

S: Significant; NS: Non-significant; T2DM: Type 2 diabetes; SNPs: Single nucleotide polymorphisms; MS: Metabolic syndrome; TNFR1: Tumor necrosis factor receptor 1.

Adiponectin

An endocrine effect leading to the clinical expression of T2DM and cardiovascular disease was attributed to the cytokines secreted by adipocytes[135,136]. Since the role of classical cytokines and adipocytokines in metabolic syndrome and associated disease conditions came to light, several workers have shown the role of activated innate immunity in the pathogenesis of T2DM[70,137]. Adiponectin levels in the plasma remain constant throughout the day and are not affected by food intake, unlike insulin and leptin.

Adipocytes secrete a plethora of cytokines, including adiponectin, resistin, leptin, IL-6, TNF-α, visfatin, RBP4, as well as free fatty acids, which alter insulin action and hepatic glucose production[138-140]. Adiponectin is a serum protein produced and secreted exclusively by adipose tissues, also known as adipocytes complement-related protein of 30 KDa (147 amino acids) (Acrp30). It is involved in the homeostatic control of circulating glucose and lipid levels[141]. Reduced adiponectin levels are documented in obese, insulin resistant and T2DM patients[116]. Adiponectin regulates glucose/lipid homeostasis via phosphorylation and activation of adenosine monophosphate activated protein kinase[142,143]. Another important function of adiponectin is to prevent the atherosclerotic vascular damage by suppressing interaction of monocytes/endothelial cells and adhesion molecules[144,145]. Therefore, high adiponectin levels are associated with reduced risk of T2DM[70]. In humans, the gene for ADIPOQ maps to chromosome 3q27. The SNPs in ADIPOQ studied by other researchers are shown in Table 6.

Table 6.

Variants of adiponectin gene and their association with type 2 diabetes and related complications in different populations

Gene variants (SNPs) Diseases Population- Ethnic groups Association Ref.
+45 G/T Obesity Iranians NS [146]
T2DM Malaysian S [147]
T2DM Greek NS [148]
MS Chinese S [149]
T2DM Japanese NS [150]
T2DM Chinese S [151]
Non-T2DM Caucasian Canadians NS [152]
T2DM Hispanic Americans NS [153]
T2DM French Caucasian NS [154]
T2DM Korean NS [155]
T2DM Caucasians S [154]
T2DM Spanish NS [156]
IGT European/Canadian NS [157]
Non-T2DM Japanese NS [158]
Obesity Swedish NS [159]
T2DM Caucasian Italians NS [160]
T2DM Caucasian Italians NS [161]
T2DM Pima Indians NS [162]
T2DM European Caucasians NS [163]
T2DM French Caucasians S [164]
+10211 T/G T2DM Asian Indians S [165]

S: Significant; NS: Non-significant; T2DM: Type 2 diabetes; SNPs: Single nucleotide polymorphisms; MS: Metabolic syndrome; IGT: Impaired glucose tolerance.

CONCLUSION

The greater tendency to diabetes in Indians may result from some genetic factors in addition to environmental and dietary factors. It is reported that the severity of diabetes (T2DM) in patients, from chronic to newly diagnosed, is related to certain biochemical and pathological examinations. The risk factors include lipid metabolism abnormalities (VLDL, HDL, LDL, TGA etc.) and relationship to body mass index, WHR, food habits and family history. Different correlation with lipid profile and response to anti-diabetic drugs are additional indications of a genetic predisposition. SNPs in specific genes which show considerable levels of variation amongst ethnic groups around the world have been implicated in the pathogenesis of diabetes. Therefore, identification of polymorphic variants of cytokine genes in different populations and the genotypic associations between SNPs and gene-gene interactions will have clinical importance as indicators of T2DM susceptibility. Association studies of cytokine genes will help in the development of prognostic markers to identify individuals at risk. The prognostic regimens arising from such genetic studies will alter and ease out treatment strategies for T2DM and related complications. Individuals at risk will be able to take prior precautionary measures and avoid or delay the onset of the disease.

Footnotes

Supported by Agencies viz Department of Biotechnology (DBT), Indian Council of Medical Research (ICMR), Department of Science and Technology (DST) and Centre of Excellence (COE), UP Government, India for generous grants to our laboratory for diabetes research

P- Reviewer: Barzilay JI, Balamuthusamy S, Hegardt FG, Trachtman H, Tsilibary PEC S- Editor: Wen LL L- Editor: Roemmele A E- Editor: Liu SQ

References

  • 1.Saxena M, Agrawal CG, Gautam S, Bid HK, Banerjee M. Overt Diabetic Complications in Obese Type 2 Diabetes Mellitus Patients from North India. Arch Appl Sci Res. 2009;1:57–66. [Google Scholar]
  • 2.IDF. Diabetes Atlas, Fifth Edition. 2012. [Google Scholar]
  • 3.Banerjee M, Saxena M. An overview and molecular genetics of type 2 diabetes mellitus. Type 2 diabetes causes treatment and preventive strategies edt. Isidoros Calpis and Stefanos Frangopoulos. Nova Publishers, New York, USA: 2012. pp. 1–64. [Google Scholar]
  • 4.Saxena M, Agrawal CC, Bid HK, Banerjee M. An interleukin-10 gene promoter polymorphism (-592A/C) associated with type 2 diabetes: a North Indian study. Biochem Genet. 2012;50:549–559. doi: 10.1007/s10528-012-9499-z. [DOI] [PubMed] [Google Scholar]
  • 5.American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2009;32:S62–S67. doi: 10.2337/dc09-S062. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327–334. doi: 10.1001/jama.286.3.327. [DOI] [PubMed] [Google Scholar]
  • 7.Banerjee M, Saxena M. Interleukin-1 (IL-1) family of cytokines: role in type 2 diabetes. Clin Chim Acta. 2012;413:1163–1170. doi: 10.1016/j.cca.2012.03.021. [DOI] [PubMed] [Google Scholar]
  • 8.Okamoto Y, Kihara S, Funahashi T, Matsuzawa Y, Libby P. Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci (Lond) 2006;110:267–278. doi: 10.1042/CS20050182. [DOI] [PubMed] [Google Scholar]
  • 9.Gruys E, Toussaint MJM, Niewold TA, Koopmans SJ. Acute phase reaction and acute phase proteins. J Zhejiang Univ Sci B. 2005;6:1045–1056. doi: 10.1631/jzus.2005.B1045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Saxena M, Srivastava N, Banerjee M. Genetic association of adiponectin gene polymorphisms (+45T/G and +10211T/G) with type 2 diabetes in North Indians. Diabetes Metab Syndr. 2012;6:65–69. doi: 10.1016/j.dsx.2012.08.008. [DOI] [PubMed] [Google Scholar]
  • 11.Bid HK, Konwar R, Aggarwal CG, Gautam S, Saxena M, Nayak VL, Banerjee M. Vitamin D receptor (FokI, BsmI and TaqI) gene polymorphisms and type 2 diabetes mellitus: a North Indian study. Indian J Med Sci. 2009;63:187–194. [PubMed] [Google Scholar]
  • 12.Bid HK, Konwar R, Saxena M, Chaudhari P, Agrawal CG, Banerjee M. Association of glutathione S-transferase (GSTM1, T1 and P1) gene polymorphisms with type 2 diabetes mellitus in north Indian population. J Postgrad Med. 2010;56:176–181. doi: 10.4103/0022-3859.68633. [DOI] [PubMed] [Google Scholar]
  • 13.Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA. 1997;94:3195–3199. doi: 10.1073/pnas.94.7.3195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Bidwell J, Keen L, Gallagher G, Kimberly R, Huizinga T, McDermott MF, Oksenberg J, McNicholl J, Pociot F, Hardt C, et al. Cytokine gene polymorphism in human disease: on-line databases. Genes Immun. 1999;1:3–19. doi: 10.1038/sj.gene.6363645. [DOI] [PubMed] [Google Scholar]
  • 15.Fernandez-Real JM, Vendrell J, Richart C, Gutierrez C, Ricart W. Platelet count and interleukin 6 gene polymorphism in healthy subjects. BMC Med Genet. 2001;2:6–11. doi: 10.1186/1471-2350-2-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Chui MH, Papanikolaou Y, Fontaine-Bisson B, Turcotte J, Wolever TM, El-Sohemy A, Chiasson JL, Rabasa-Lhoret R, Maheux P, Ryan E, et al. The TNF-alpha-238G & gt; a single-nucleotide polymorphism protects against memory decline in older adults with type 2 diabetes. Behav Neurosci. 2007;121:619–624. doi: 10.1037/0735-7044.121.3.619. [DOI] [PubMed] [Google Scholar]
  • 17.Bid HK, Konwar R, Agrawal CG, Banerjee M. Association of IL-4 and IL-1RN (receptor antagonist) gene variants and the risk of type 2 diabetes mellitus: a study in the north Indian population. Indian J Med Sci. 2008;62:259–266. [PubMed] [Google Scholar]
  • 18.Ezzidi I, Mtiraoui N, Kacem M, Mallat SG, Mohamed MB, Chaieb M, Mahjoub T, Almawi WY. Interleukin-10-592C/A, -819C/T and -1082A/G promoter variants affect the susceptibility to nephropathy in Tunisian type 2 diabetes (T2DM) patients. Clin Endocrinol (Oxf) 2009;70:401–407. doi: 10.1111/j.1365-2265.2008.03337.x. [DOI] [PubMed] [Google Scholar]
  • 19.Koh SJ, Jang Y, Hyun YJ, Park JY, Song YD, Shin KK, Chae JS, Kim BK, Ordovas JM, Lee JH. Interleukin-6 (IL-6) -572C--& gt; G promoter polymorphism is associated with type 2 diabetes risk in Koreans. Clin Endocrinol (Oxf) 2009;70:238–244. doi: 10.1111/j.1365-2265.2008.03315.x. [DOI] [PubMed] [Google Scholar]
  • 20.Mtiraoui N, Ezzidi I, Kacem M, Ben Hadj Mohamed M, Chaieb M, Haj Jilani AB, Mahjoub T, Almawi WY. Predictive value of interleukin-10 promoter genotypes and haplotypes in determining the susceptibility to nephropathy in type 2 diabetes patients. Diabetes Metab Res Rev. 2009;25:57–63. doi: 10.1002/dmrr.892. [DOI] [PubMed] [Google Scholar]
  • 21.D’Alfonso S, Rampi M, Bocchio D, Colombo G, Scorza-Smeraldi R, Momigliano-Richardi P. Systemic lupus erythematosus candidate genes in the Italian population: evidence for a significant association with interleukin-10. Arthritis Rheum. 2000;43:120–128. doi: 10.1002/1529-0131(200001)43:1<120::AID-ANR15>3.0.CO;2-3. [DOI] [PubMed] [Google Scholar]
  • 22.Mantovani A, Locati M, Vecchi A, Sozzani S, Allavena P. Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends Immunol. 2001;22:328–336. doi: 10.1016/s1471-4906(01)01941-x. [DOI] [PubMed] [Google Scholar]
  • 23.Haukim N, Bidwell JL, Smith AJ, Keen LJ, Gallagher G, Kimberly R, Huizinga T, McDermott MF, Oksenberg J, McNicholl J, et al. Cytokine gene polymorphism in human disease: on-line databases, supplement 2. Genes Immun. 2002;3:313–330. doi: 10.1038/sj.gene.6363881. [DOI] [PubMed] [Google Scholar]
  • 24.Welsh N, Cnop M, Kharroubi I, Bugliani M, Lupi R, Marchetti P, Eizirik DL. Is there a role for locally produced interleukin-1 in the deleterious effects of high glucose or the type 2 diabetes milieu to human pancreatic islets? Diabetes. 2005;54:3238–3244. doi: 10.2337/diabetes.54.11.3238. [DOI] [PubMed] [Google Scholar]
  • 25.Steinkasserer A, Spurr NK, Cox S, Jeggo P, Sim RB. The human IL-1 receptor antagonist gene (IL1RN) maps to chromosome 2q14-q21, in the region of the IL-1 alpha and IL-1 beta loci. Genomics. 1992;13:654–657. doi: 10.1016/0888-7543(92)90137-h. [DOI] [PubMed] [Google Scholar]
  • 26.López NJ, Valenzuela CY, Jara L. Interleukin-1 gene cluster polymorphisms associated with periodontal disease in type 2 diabetes. J Periodontol. 2009;80:1590–1598. doi: 10.1902/jop.2009.090134. [DOI] [PubMed] [Google Scholar]
  • 27.Bensen JT, Langefeld CD, Li L, McCall CE, Cousart SL, Dryman BN, Freedman BI, Bowden DW. Association of an IL-1A 3’UTR polymorphism with end-stage renal disease and IL-1 alpha expression. Kidney Int. 2003;63:1211–1219. doi: 10.1046/j.1523-1755.2003.00856.x. [DOI] [PubMed] [Google Scholar]
  • 28.Mookherjee S, Banerjee D, Chakraborty S, Banerjee A, Mukhopadhyay I, Sen A, Ray K. Association of IL1A and IL1B loci with primary open angle glaucoma. BMC Med Genet. 2010;11:99. doi: 10.1186/1471-2350-11-99. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Abrahamian H, Endler G, Exner M, Mauler H, Raith M, Endler L, Rumpold H, Gerdov M, Mannhalter C, Prager R, Irsigler K, Wagner OF. Association of low-grade inflammation with nephropathy in type 2 diabetic patients: role of elevated CRP-levels and 2 different gene-polymorphisms of proinflammatory cytokines. Exp Clin Endocrinol Diabetes. 2007;115:38–41. doi: 10.1055/s-2007-948213. [DOI] [PubMed] [Google Scholar]
  • 30.Krikovsky D, Vásárhelyi B, Treszl A, Körner A, Tordai A, Tulassay T, Madácsy L. Genetic polymorphism of interleukin-1beta is associated with risk of type 1 diabetes mellitus in children. Eur J Pediatr. 2002;161:507–508. doi: 10.1007/s00431-002-1030-9. [DOI] [PubMed] [Google Scholar]
  • 31.Achyut BR, Srivastava A, Bhattacharya S, Mittal B. Genetic association of interleukin-1beta (-511C/T) and interleukin-1 receptor antagonist (86 bp repeat) polymorphisms with Type 2 diabetes mellitus in North Indians. Clin Chim Acta. 2007;377:163–169. doi: 10.1016/j.cca.2006.09.012. [DOI] [PubMed] [Google Scholar]
  • 32.Lee YY, Lee NS, Cho YM, Moon MK, Jung HS, Park YJ, Park HJ, Youn BS, Lee HK, Park KS, et al. Genetic association study of adiponectin polymorphisms with risk of Type 2 diabetes mellitus in Korean population. Diabet Med. 2005;22:569–575. doi: 10.1111/j.1464-5491.2005.01460.x. [DOI] [PubMed] [Google Scholar]
  • 33.Lee SH, Ihm CG, Sohn SD, Lee TW, Kim MJ, Koh G, Oh SJ, Woo JT, Kim SW, Kim JW, et al. Polymorphisms in interleukin-1 beta and Interleukin-1 receptor antagonist genes are associated with kidney failure in Korean patients with type 2 diabetes mellitus. Am J Nephrol. 2014;24:410–414. doi: 10.1159/000080044. [DOI] [PubMed] [Google Scholar]
  • 34.Blakemore AI, Cox A, Gonzalez AM, Maskil JK, Hughes ME, Wilson RM, Ward JD, Duff GW. Interleukin-1 receptor antagonist allele (IL1RN*2) associated with nephropathy in diabetes mellitus. Hum Genet. 1996;97:369–374. doi: 10.1007/BF02185776. [DOI] [PubMed] [Google Scholar]
  • 35.Ruotsalainen E, Salmenniemi U, Vauhkonen I, Pihlajamäki J, Punnonen K, Kainulainen S, Laakso M. Changes in inflammatory cytokines are related to impaired glucose tolerance in offspring of type 2 diabetic subjects. Diabetes Care. 2006;29:2714–2720. doi: 10.2337/dc06-0147. [DOI] [PubMed] [Google Scholar]
  • 36.Perrier S, Darakhshan F, Hajduch E. IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde? FEBS Lett. 2006;580:6289–6294. doi: 10.1016/j.febslet.2006.10.061. [DOI] [PubMed] [Google Scholar]
  • 37.Zemunik T, Skrabic V, Boraska V, Diklic D, Terzic IM, Capkun V, Peruzovic M, Terzic J. FokI polymorphism, vitamin D receptor, and interleukin-1 receptor haplotypes are associated with type 1 diabetes in the Dalmatian population. J Mol Diagn. 2005;7:600–604. doi: 10.1016/S1525-1578(10)60593-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Opstad TB, Pettersen AÅ, Arnesen H, Seljeflot I. Circulating levels of IL-18 are significantly influenced by the IL-18 +183 A/G polymorphism in coronary artery disease patients with diabetes type 2 and the metabolic syndrome: an observational study. Cardiovasc Diabetol. 2011;10:110. doi: 10.1186/1475-2840-10-110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Huang Y, Xu M, Hong J, Gu W, Bi Y, Li X. -607 C/A polymorphism in the promoter of IL-18 gene is associated with 2 h post-loading plasma glucose level in Chinese. Endocrine. 2010;37:507–512. doi: 10.1007/s12020-010-9338-0. [DOI] [PubMed] [Google Scholar]
  • 40.He M, Cornelis MC, Kraft P, van Dam RM, Sun Q, Laurie CC, Mirel DB, Chasman DI, Ridker PM, Hunter DJ, et al. Genome-wide association study identifies variants at the IL18-BCO2 locus associated with interleukin-18 levels. Arterioscler Thromb Vasc Biol. 2010;30:885–890. doi: 10.1161/ATVBAHA.109.199422. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Rafiq S, Melzer D, Weedon MN, Lango H, Saxena R, Scott LJ, Palmer CN, Morris AD, McCarthy MI, Ferrucci L, et al. Gene variants influencing measures of inflammation or predisposing to autoimmune and inflammatory diseases are not associated with the risk of type 2 diabetes. Diabetologia. 2008;51:2205–2213. doi: 10.1007/s00125-008-1160-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Thompson SR, Sanders J, Stephens JW, Miller GJ, Humphries SE. A common interleukin 18 haplotype is associated with higher body mass index in subjects with diabetes and coronary heart disease. Metabolism. 2007;56:662–669. doi: 10.1016/j.metabol.2006.12.015. [DOI] [PubMed] [Google Scholar]
  • 43.Conti B, Jahng JW, Tinti C, Son JH, Joh TH. Induction of interferon-gamma inducing factor in the adrenal cortex. J Biol Chem. 1997;272:2035–2037. doi: 10.1074/jbc.272.4.2035. [DOI] [PubMed] [Google Scholar]
  • 44.Matsui K, Yoshimoto T, Tsutsui H, Hyodo Y, Hayashi N, Hiroishi K, Kawada N, Okamura H, Nakanishi K, Higashino K. Propionibacterium acnes treatment diminishes CD4+ NK1.1+ T cells but induces type I T cells in the liver by induction of IL-12 and IL-18 production from Kupffer cells. J Immunol. 1997;159:97–106. [PubMed] [Google Scholar]
  • 45.Stoll S, Müller G, Kurimoto M, Saloga J, Tanimoto T, Yamauchi H, Okamura H, Knop J, Enk AH. Production of IL-18 (IFN-gamma-inducing factor) messenger RNA and functional protein by murine keratinocytes. J Immunol. 1997;159:298–302. [PubMed] [Google Scholar]
  • 46.Udagawa N, Horwood NJ, Elliott J, Mackay A, Owens J, Okamura H, Kurimoto M, Chambers TJ, Martin TJ, Gillespie MT. Interleukin-18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation. J Exp Med. 1997;185:1005–1012. doi: 10.1084/jem.185.6.1005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Stoll S, Jonuleit H, Schmitt E, Müller G, Yamauchi H, Kurimoto M, Knop J, Enk AH. Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development. Eur J Immunol. 1998;28:3231–3239. doi: 10.1002/(SICI)1521-4141(199810)28:10<3231::AID-IMMU3231>3.0.CO;2-Q. [DOI] [PubMed] [Google Scholar]
  • 48.Gracie JA, Forsey RJ, Chan WL, Gilmour A, Leung BP, Greer MR, Kennedy K, Carter R, Wei XQ, Xu D, et al. A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest. 1999;104:1393–1401. doi: 10.1172/JCI7317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Pizarro TT, Michie MH, Bentz M, Woraratanadharm J, Smith MF, Foley E, Moskaluk CA, Bickston SJ, Cominelli F. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn’s disease: expression and localization in intestinal mucosal cells. J Immunol. 1999;162:6829–6835. [PubMed] [Google Scholar]
  • 50.Prinz M, Hanisch UK. Murine microglial cells produce and respond to interleukin-18. J Neurochem. 1999;72:2215–2218. doi: 10.1046/j.1471-4159.1999.0722215.x. [DOI] [PubMed] [Google Scholar]
  • 51.Gu Y, Kuida K, Tsutsui H, Ku G, Hsiao K, Fleming MA, Hayashi N, Higashino K, Okamura H, Nakanishi K, et al. Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme. Science. 1997;275:206–209. doi: 10.1126/science.275.5297.206. [DOI] [PubMed] [Google Scholar]
  • 52.Parnet P, Garka KE, Bonnert TP, Dower SK, Sims JE. IL-1Rrp is a novel receptor-like molecule similar to the type I interleukin-1 receptor and its homologues T1/ST2 and IL-1R AcP. J Biol Chem. 1996;271:3967–3970. doi: 10.1074/jbc.271.8.3967. [DOI] [PubMed] [Google Scholar]
  • 53.Torigoe K, Ushio S, Okura T, Kobayashi S, Taniai M, Kunikata T, Murakami T, Sanou O, Kojima H, Fujii M, et al. Purification and characterization of the human interleukin-18 receptor. J Biol Chem. 1997;272:25737–25742. doi: 10.1074/jbc.272.41.25737. [DOI] [PubMed] [Google Scholar]
  • 54.Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity. 1999;10:127–136. doi: 10.1016/s1074-7613(00)80013-8. [DOI] [PubMed] [Google Scholar]
  • 55.Frigerio S, Holländer GA, Zumsteg U. Functional IL-18 Is produced by primary pancreatic mouse islets and NIT-1 beta cells and participates in the progression towards destructive insulitis. Horm Res. 2002;57:94–104. doi: 10.1159/000057959. [DOI] [PubMed] [Google Scholar]
  • 56.Mallat Z, Corbaz A, Scoazec A, Besnard S, Lesèche G, Chvatchko Y, Tedgui A. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation. 2001;104:1598–1603. doi: 10.1161/hc3901.096721. [DOI] [PubMed] [Google Scholar]
  • 57.Aso Y, Okumura K, Takebayashi K, Wakabayashi S, Inukai T. Relationships of plasma interleukin-18 concentrations to hyperhomocysteinemia and carotid intimal-media wall thickness in patients with type 2 diabetes. Diabetes Care. 2003;26:2622–2627. doi: 10.2337/diacare.26.9.2622. [DOI] [PubMed] [Google Scholar]
  • 58.Esposito K, Nappo F, Giugliano F, Di Palo C, Ciotola M, Barbieri M, Paolisso G, Giugliano D. Cytokine milieu tends toward inflammation in type 2 diabetes. Diabetes Care. 2003;26:1647. doi: 10.2337/diacare.26.5.1647. [DOI] [PubMed] [Google Scholar]
  • 59.Blazhev A, Nicolff G, Petrova Ch, Jordanova-Laleva P. Serum levels of interleukin 12 and interleukin 18 in diabetic children. Diabetologia Croatica. 2006;35:1–6. [Google Scholar]
  • 60.Hung J, McQuillan BM, Chapman CM, Thompson PL, Beilby JP. Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arterioscler Thromb Vasc Biol. 2005;25:1268–1273. doi: 10.1161/01.ATV.0000163843.70369.12. [DOI] [PubMed] [Google Scholar]
  • 61.Sarvetnick N. IFN-gamma, IGIF, and IDDM. J Clin Invest. 1997;99:371–372. doi: 10.1172/JCI119167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Hülsmeyer M, Scheufler C, Dreyer MK. Structure of interleukin 4 mutant E9A suggests polar steering in receptor-complex formation. Acta Crystallogr D Biol Crystallogr. 2001;57:1334–1336. doi: 10.1107/s0907444901009799. [DOI] [PubMed] [Google Scholar]
  • 63.Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87:2095–2147. [PubMed] [Google Scholar]
  • 64.Kazemi Arababadi M. Interleukin-4 gene polymorphisms in type 2 diabetic patients with nephropathy. Iran J Kidney Dis. 2010;4:302–306. [PubMed] [Google Scholar]
  • 65.Ho KT, Shiau MY, Chang YH, Chen CM, Yang SC, Huang CN. Association of interleukin-4 promoter polymorphisms in Taiwanese patients with type 2 diabetes mellitus. Metabolism. 2010;59:1717–1722. doi: 10.1016/j.metabol.2010.04.010. [DOI] [PubMed] [Google Scholar]
  • 66.Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997;82:4196–4200. doi: 10.1210/jcem.82.12.4450. [DOI] [PubMed] [Google Scholar]
  • 67.Fried SK, Ricci MR, Russell CD, Laferrère B. Regulation of leptin production in humans. J Nutri. 1998;130:3127S–3131S. doi: 10.1093/jn/130.12.3127S. [DOI] [PubMed] [Google Scholar]
  • 68.Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes. 2005;54 Suppl 2:S114–S124. doi: 10.2337/diabetes.54.suppl_2.s114. [DOI] [PubMed] [Google Scholar]
  • 69.Cardellini M, Perego L, D’Adamo M, Marini MA, Procopio C, Hribal ML, Andreozzi F, Frontoni S, Giacomelli M, Paganelli M, et al. C-174G polymorphism in the promoter of the interleukin-6 gene is associated with insulin resistance. Diabetes Care. 2005;28:2007–2012. doi: 10.2337/diacare.28.8.2007. [DOI] [PubMed] [Google Scholar]
  • 70.Spranger J, Kroke A, Möhlig M, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF. Adiponectin and protection against type 2 diabetes mellitus. Lancet. 2003;361:226–228. doi: 10.1016/S0140-6736(03)12255-6. [DOI] [PubMed] [Google Scholar]
  • 71.Qi L, van Dam RM, Meigs JB, Manson JE, Hunter D, Hu FB. Genetic variation in IL6 gene and type 2 diabetes: tagging-SNP haplotype analysis in large-scale case-control study and meta-analysis. Hum Mol Genet. 2006;15:1914–1920. doi: 10.1093/hmg/ddl113. [DOI] [PubMed] [Google Scholar]
  • 72.Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998;102:1369–1376. doi: 10.1172/JCI2629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Terry CF, Loukaci V, Green FR. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem. 2000;275:18138–18144. doi: 10.1074/jbc.M000379200. [DOI] [PubMed] [Google Scholar]
  • 74.Kubaszek A, Pihlajamäki J, Komarovski V, Lindi V, Lindström J, Eriksson J, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, et al. Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes. 2003;52:1872–1876. doi: 10.2337/diabetes.52.7.1872. [DOI] [PubMed] [Google Scholar]
  • 75.Vozarova B, Fernández-Real JM, Knowler WC, Gallart L, Hanson RL, Gruber JD, Ricart W, Vendrell J, Richart C, Tataranni PA, et al. The interleukin-6 (-174) G/C promoter polymorphism is associated with type-2 diabetes mellitus in Native Americans and Caucasians. Hum Genet. 2003;112:409–413. doi: 10.1007/s00439-003-0912-x. [DOI] [PubMed] [Google Scholar]
  • 76.Illig T, Bongardt F, Schöpfer A, Müller-Scholze S, Rathmann W, Koenig W, Thorand B, Vollmert C, Holle R, Kolb H, et al. Significant association of the interleukin-6 gene polymorphisms C-174G and A-598G with type 2 diabetes. J Clin Endocrinol Metab. 2004;89:5053–5058. doi: 10.1210/jc.2004-0355. [DOI] [PubMed] [Google Scholar]
  • 77.Himelfarb ST, Silva FA, Arazi SS, Farjado CM, Garofalo A, Bertolami MC, Bertolami A, Faludi A, Sampaio MF, Rezende AA, et al. Tumor necrosis factor-α and interleukin-6 expression in leukocytes and their association with polymorphisms and bone markers in diabetic individuals treated with pioglitazone. Drug Metabol Drug Interact. 2011;26:37–40. doi: 10.1515/DMDI.2011.100. [DOI] [PubMed] [Google Scholar]
  • 78.Underwood PC, Chamarthi B, Williams JS, Sun B, Vaidya A, Raby BA, Lasky-Su J, Hopkins PN, Adler GK, Williams GH. Replication and meta-analysis of the gene-environment interaction between body mass index and the interleukin-6 promoter polymorphism with higher insulin resistance. Metabolism. 2012;61:667–671. doi: 10.1016/j.metabol.2011.09.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Popko K, Gorska E, Demkow U. Influence of interleukin-6 and G174C polymorphism in IL-6 gene on obesity and energy balance. Eur J Med Res. 2010;15 Suppl 2:123–127. doi: 10.1186/2047-783X-15-S2-123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Mendoza-Carrera F, Ramírez-López G, Ayala-Martínez NA, García-Zapién AG, Flores-Martínez SE, Sánchez-Corona J. Influence of CRP, IL6, and TNFA gene polymorphisms on circulating levels of C-reactive protein in Mexican adolescents. Arch Med Res. 2010;41:472–477. doi: 10.1016/j.arcmed.2010.08.015. [DOI] [PubMed] [Google Scholar]
  • 81.Mukhopadhyaya PN, Acharya A, Chavan Y, Purohit SS, Mutha A. Metagenomic study of single-nucleotide polymorphism within candidate genes associated with type 2 diabetes in an Indian population. Genet Mol Res. 2010;9:2060–2068. doi: 10.4238/vol9-4gmr883. [DOI] [PubMed] [Google Scholar]
  • 82.Kilpeläinen TO, Laaksonen DE, Lakka TA, Herder C, Koenig W, Lindström J, Eriksson JG, Uusitupa M, Kolb H, Laakso M, et al. The rs1800629 polymorphism in the TNF gene interacts with physical activity on the changes in C-reactive protein levels in the Finnish Diabetes Prevention Study. Exp Clin Endocrinol Diabetes. 2010;118:757–759. doi: 10.1055/s-0030-1249686. [DOI] [PubMed] [Google Scholar]
  • 83.Bouhaha R, Baroudi T, Ennafaa H, Vaillant E, Abid H, Sassi R, Vatin V, Froguel P, Gaaied AB, Meyre D, et al. Study of TNFalpha -308G/A and IL6 -174G/C polymorphisms in type 2 diabetes and obesity risk in the Tunisian population. Clin Biochem. 2010;43:549–552. doi: 10.1016/j.clinbiochem.2010.01.008. [DOI] [PubMed] [Google Scholar]
  • 84.Huth C, Illig T, Herder C, Gieger C, Grallert H, Vollmert C, Rathmann W, Hamid YH, Pedersen O, Hansen T, et al. Joint analysis of individual participants’ data from 17 studies on the association of the IL6 variant -174G& gt; C with circulating glucose levels, interleukin-6 levels, and body mass index. Ann Med. 2009;41:128–138. doi: 10.1080/07853890802337037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Oberbach A, Lehmann S, Kirsch K, Krist J, Sonnabend M, Linke A, Tönjes A, Stumvoll M, Blüher M, Kovacs P. Long-term exercise training decreases interleukin-6 (IL-6) serum levels in subjects with impaired glucose tolerance: effect of the -174G/C variant in IL-6 gene. Eur J Endocrinol. 2008;159:129–136. doi: 10.1530/EJE-08-0220. [DOI] [PubMed] [Google Scholar]
  • 86.Rudofsky G, Schlotterer A, Reismann P, Engel J, Grafe IA, Tafel J, Morcos M, Humpert PM, Nawroth P, Bierhaus A, et al. The -174G& gt; C IL-6 gene promoter polymorphism and diabetic microvascular complications. Horm Metab Res. 2009;41:308–313. doi: 10.1055/s-0028-1119373. [DOI] [PubMed] [Google Scholar]
  • 87.Testa R, Olivieri F, Bonfigli AR, Sirolla C, Boemi M, Marchegiani F, Marra M, Cenerelli S, Antonicelli R, Dolci A, et al. Interleukin-6-174 G & gt; C polymorphism affects the association between IL-6 plasma levels and insulin resistance in type 2 diabetic patients. Diabetes Res Clin Pract. 2006;71:299–305. doi: 10.1016/j.diabres.2005.07.007. [DOI] [PubMed] [Google Scholar]
  • 88.Illig T, Bongardt F, Schöpfer-Wendels A, Huth C, Heid I, Rathmann W, Martin S, Vollmert C, Holle R, Thorand B, et al. Genetics of type 2 diabetes: impact of interleukin-6 gene variants. Gesundheitswesen. 2005;67 Suppl 1:S122–S126. doi: 10.1055/s-2005-858396. [DOI] [PubMed] [Google Scholar]
  • 89.Herbert A, Liu C, Karamohamed S, Schiller J, Liu J, Yang Q, Wilson PW, Cupples LA, Meigs JB. The -174 IL-6 GG genotype is associated with a reduced risk of type 2 diabetes mellitus in a family sample from the National Heart, Lung and Blood Institute’s Framingham Heart Study. Diabetologia. 2005;48:1492–1495. doi: 10.1007/s00125-005-1830-3. [DOI] [PubMed] [Google Scholar]
  • 90.Mostafazadeh A, Herder C, Haastert B, Hanifi-Moghaddam P, Schloot N, Koenig W, Illig T, Thorand B, Holle R, Eslami MB, et al. Association of humoral immunity to human Hsp60 with the IL-6 gene polymorphism C-174G in patients with type 2 diabetes and controls. Horm Metab Res. 2005;37:257–263. doi: 10.1055/s-2005-861209. [DOI] [PubMed] [Google Scholar]
  • 91.Chang YH, Huang CN, Shiau MY. The C-174G promoter polymorphism of the interleukin-6 (IL-6) gene that affects insulin sensitivity in Caucasians is not involved in the pathogenesis of Taiwanese type 2 diabetes mellitus. Eur Cytokine Netw. 2004;15:117–119. [PubMed] [Google Scholar]
  • 92.Möhlig M, Boeing H, Spranger J, Osterhoff M, Kroke A, Fisher E, Bergmann MM, Ristow M, Hoffmann K, Pfeiffer AF. Body mass index and C-174G interleukin-6 promoter polymorphism interact in predicting type 2 diabetes. J Clin Endocrinol Metab. 2004;89:1885–1890. doi: 10.1210/jc.2003-031101. [DOI] [PubMed] [Google Scholar]
  • 93.Kubaszek A, Pihlajamäki J, Punnonen K, Karhapää P, Vauhkonen I, Laakso M. The C-174G promoter polymorphism of the IL-6 gene affects energy expenditure and insulin sensitivity. Diabetes. 2003;52:558–561. doi: 10.2337/diabetes.52.2.558. [DOI] [PubMed] [Google Scholar]
  • 94.Fernandez-Real JM, Broch M, Vendrell J, Gutiérrez C, Casamitjana R, Pugeat M, Richart C, Ricart W. Interleukin-6 gene polymorphism and insulin sensitivity. Diabetes. 2000;49:517–520. doi: 10.2337/diabetes.49.3.517. [DOI] [PubMed] [Google Scholar]
  • 95.Libra M, Signorelli SS, Bevelacqua Y, Navolanic PM, Bevelacqua V, Polesel J, Talamini R, Stivala F, Mazzarino MC, Malaponte G. Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease. J Clin Pathol. 2006;59:211–215. doi: 10.1136/jcp.2004.025452. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96.Xiao LM, Yan YX, Xie CJ, Fan WH, Xuan DY, Wang CX, Chen L, Sun SY, Xie BY, Zhang JC. Association among interleukin-6 gene polymorphism, diabetes and periodontitis in a Chinese population. Oral Dis. 2009;15:547–553. doi: 10.1111/j.1601-0825.2009.01584.x. [DOI] [PubMed] [Google Scholar]
  • 97.Zhang X, Ma L, Peng F, Wu Y, Chen Y, Yu L, Lei Z, Zhang C. The endothelial dysfunction in patients with type 2 diabetes mellitus is associated with IL-6 gene promoter polymorphism in Chinese population. Endocrine. 2011;40:124–129. doi: 10.1007/s12020-011-9442-9. [DOI] [PubMed] [Google Scholar]
  • 98.Huth C, Heid IM, Vollmert C, Gieger C, Grallert H, Wolford JK, Langer B, Thorand B, Klopp N, Hamid YH, et al. IL6 gene promoter polymorphisms and type 2 diabetes: joint analysis of individual participants’ data from 21 studies. Diabetes. 2006;55:2915–2921. doi: 10.2337/db06-0600. [DOI] [PubMed] [Google Scholar]
  • 99.Arora P, Garcia-Bailo B, Dastani Z, Brenner D, Villegas A, Malik S, Spector TD, Richards B, El-Sohemy A, Karmali M, et al. Genetic polymorphisms of innate immunity-related inflammatory pathways and their association with factors related to type 2 diabetes. BMC Med Genet. 2011;12:95. doi: 10.1186/1471-2350-12-95. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100.Navarro-González JF, Muros M, Mora-Fernández C, Herrera H, Meneses B, García J. Pentoxifylline for renoprotection in diabetic nephropathy: the PREDIAN study. Rationale and basal results. J Diabetes Complications. 2010;25:314–319. doi: 10.1016/j.jdiacomp.2010.09.003. [DOI] [PubMed] [Google Scholar]
  • 101.Ng DP, Nurbaya S, Ye SH, Krolewski AS. An IL-6 haplotype on human chromosome 7p21 confers risk for impaired renal function in type 2 diabetic patients. Kidney Int. 2008;74:521–527. doi: 10.1038/ki.2008.202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 102.Pakala SV, Kurrer MO, Katz JD. T helper 2 (Th2) T cells induce acute pancreatitis and diabetes in immune-compromised nonobese diabetic (NOD) mice. J Exp Med. 1997;186:299–306. doi: 10.1084/jem.186.2.299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103.van Exel E, Gussekloo J, de Craen AJ, Bootsma-van der Wiel A, Frölich M, Westendorp RG. Inflammation and stroke: the Leiden 85-Plus Study. Stroke. 2002;33:1135–1138. doi: 10.1161/01.str.0000014206.05597.9e. [DOI] [PubMed] [Google Scholar]
  • 104.Sankaran D, Asderakis A, Ashraf S, Roberts IS, Short CD, Dyer PA, Sinnott PJ, Hutchinson IV. Cytokine gene polymorphisms predict acute graft rejection following renal transplantation. Kidney Int. 1999;56:281–288. doi: 10.1046/j.1523-1755.1999.00536.x. [DOI] [PubMed] [Google Scholar]
  • 105.Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997;24:1–8. doi: 10.1111/j.1365-2370.1997.tb00001.x. [DOI] [PubMed] [Google Scholar]
  • 106.Tsiavou A, Hatziagelaki E, Chaidaroglou A, Manginas A, Koniavitou K, Degiannis D, Raptis SA. TNF-alpha, TGF-beta1, IL-10, IL-6, gene polymorphisms in latent autoimmune diabetes of adults (LADA) and type 2 diabetes mellitus. J Clin Immunol. 2004;24:591–599. doi: 10.1007/s10875-004-6239-0. [DOI] [PubMed] [Google Scholar]
  • 107.Chang YH, Huang CN, Wu CY, Shiau MY. Association of interleukin-10 A-592C and T-819C polymorphisms with type 2 diabetes mellitus. Hum Immunol. 2005;66:1258–1263. doi: 10.1016/j.humimm.2005.05.001. [DOI] [PubMed] [Google Scholar]
  • 108.Arababadi MK, Reza Mirzaei M, Ali Sajadi SM, Hassanshahi G, Ahmadabadi BN, Salehabadi VA, Derakhshan R, Kennedy D. Interleukin (IL)-10 gene polymorphisms are associated with type 2 diabetes with and without nephropathy: a study of patients from the southeast region of Iran. Inflammation. 2012;35:797–802. doi: 10.1007/s10753-011-9376-7. [DOI] [PubMed] [Google Scholar]
  • 109.Yin YW, Sun QQ, Zhang BB, Hu AM, Liu HL, Wang Q, Zeng YH, Xu RJ, Ma JB, Shi LB. Association between interleukin-10 gene -592 C/A polymorphism and the risk of type 2 diabetes mellitus: a meta-analysis of 5320 subjects. Hum Immunol. 2012;73:960–965. doi: 10.1016/j.humimm.2012.06.006. [DOI] [PubMed] [Google Scholar]
  • 110.Paine SK, Sen A, Choudhuri S, Mondal LK, Chowdhury IH, Basu A, Mukherjee A, Bhattacharya B. Association of tumor necrosis factor α, interleukin 6, and interleukin 10 promoter polymorphism with proliferative diabetic retinopathy in type 2 diabetic subjects. Retina. 2012;32:1197–1203. doi: 10.1097/IAE.0b013e31822f55f3. [DOI] [PubMed] [Google Scholar]
  • 111.Kolla VK, Madhavi G, Pulla Reddy B, Srikanth Babu BM, Yashovanthi J, Valluri VL, Ramesh J, Akka J. Association of tumor necrosis factor alpha, interferon gamma and interleukin 10 gene polymorphisms with peripheral neuropathy in South Indian patients with type 2 diabetes. Cytokine. 2009;47:173–177. doi: 10.1016/j.cyto.2009.06.007. [DOI] [PubMed] [Google Scholar]
  • 112.Scarpelli D, Cardellini M, Andreozzi F, Laratta E, Hribal ML, Marini MA, Tassi V, Lauro R, Perticone F, Sesti G. Variants of the interleukin-10 promoter gene are associated with obesity and insulin resistance but not type 2 diabetes in caucasian italian subjects. Diabetes. 2006;55:1529–1533. doi: 10.2337/db06-0047. [DOI] [PubMed] [Google Scholar]
  • 113.Erdogan M, Cetinkalp S, Ozgen AG, Saygili F, Berdeli A, Yilmaz C. Interleukin-10 (-1082G/A) gene polymorphism in patients with type 2 diabetes with and without nephropathy. Genet Test Mol Biomarkers. 2012;16:91–94. doi: 10.1089/gtmb.2011.0075. [DOI] [PubMed] [Google Scholar]
  • 114.Kung WJ, Lin CC, Liu SH, Chaung HC. Association of interleukin-10 polymorphisms with cytokines in type 2 diabetic nephropathy. Diabetes Technol Ther. 2010;12:809–813. doi: 10.1089/dia.2010.0085. [DOI] [PubMed] [Google Scholar]
  • 115.Forte GI, Pilato G, Vaccarino L, Sanacore M, Candore G, Romano GC, Testa R, Franceschi C, Capri M, Marra M, et al. Risk profiles in type 2 diabetes (metabolic syndrome): integration of IL-10 polymorphisms and laboratory parameters to identify vascular damages related complications. Curr Pharm Des. 2010;16:898–903. doi: 10.2174/138161210790883642. [DOI] [PubMed] [Google Scholar]
  • 116.Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000;20:1595–1599. doi: 10.1161/01.atv.20.6.1595. [DOI] [PubMed] [Google Scholar]
  • 117.Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes. 1994;43:1271–1278. doi: 10.2337/diab.43.11.1271. [DOI] [PubMed] [Google Scholar]
  • 118.Tsiotra PC, Tsigos C, Raptis SA. TNFalpha and leptin inhibit basal and glucose-stimulated insulin secretion and gene transcription in the HIT-T15 pancreatic cells. Int J Obes Relat Metab Disord. 2001;25:1018–1026. doi: 10.1038/sj.ijo.0801657. [DOI] [PubMed] [Google Scholar]
  • 119.Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol. 1997;34:391–399. doi: 10.1016/s0161-5890(97)00052-7. [DOI] [PubMed] [Google Scholar]
  • 120.Guzmán-Flores JM, Muñoz-Valle JF, Sánchez-Corona J, Cobián JG, Medina-Carrillo L, García-Zapién AG, Cruz-Quevedo EG, Flores-Martínez SE. Tumor necrosis factor-alpha gene promoter -308G/A and -238G/A polymorphisms in Mexican patients with type 2 diabetes mellitus. Dis Markers. 2011;30:19–24. doi: 10.3233/DMA-2011-0759. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 121.Vendrell J, Fernandez-Real JM, Gutierrez C, Zamora A, Simon I, Bardaji A, Ricart W, Richart C. A polymorphism in the promoter of the tumor necrosis factor-alpha gene (-308) is associated with coronary heart disease in type 2 diabetic patients. Atherosclerosis. 2003;167:257–264. doi: 10.1016/s0021-9150(02)00429-x. [DOI] [PubMed] [Google Scholar]
  • 122.Shiau MY, Wu CY, Huang CN, Hu SW, Lin SJ, Chang YH. TNF-alpha polymorphisms and type 2 diabetes mellitus in Taiwanese patients. Tissue Antigens. 2003;61:393–397. doi: 10.1034/j.1399-0039.2003.00059.x. [DOI] [PubMed] [Google Scholar]
  • 123.Mustapic M, Popovic Hadzija M, Pavlovic M, Pavkovic P, Presecki P, Mrazovac D, Mimica N, Korolija M, Pivac N, Muck-Seler D. Alzheimer’s disease and type 2 diabetes: the association study of polymorphisms in tumor necrosis factor-alpha and apolipoprotein E genes. Metab Brain Dis. 2012;27:507–512. doi: 10.1007/s11011-012-9310-1. [DOI] [PubMed] [Google Scholar]
  • 124.Liu B, Yu N, Tan LS, Liu JB, Guo Y, Pan YP. [A study of frequency of TNF alpha gene with type 2 diabetes mellitus with chronic periodontitis] Shanghai Kouqiang Yixue. 2011;20:169–173. [PubMed] [Google Scholar]
  • 125.Sobti RC, Kler R, Sharma YP, Talwar KK, Singh N. Risk of obesity and type 2 diabetes with tumor necrosis factor-α 308G/A gene polymorphism in metabolic syndrome and coronary artery disease subjects. Mol Cell Biochem. 2012;360:1–7. doi: 10.1007/s11010-011-0917-z. [DOI] [PubMed] [Google Scholar]
  • 126.Perez-Luque E, Malacara JM, Garay-Sevilla ME, Fajardo ME. Association of the TNF-α -308G/A polymorphism with family history of type 2 diabetes mellitus in a Mexican population. Clin Biochem. 2012;45:12–15. doi: 10.1016/j.clinbiochem.2011.09.018. [DOI] [PubMed] [Google Scholar]
  • 127.Ferreira AP, Ferreira CB, Souza VC, Furioso AC, Toledo JO, Moraes CF, Córdova C, Nóbrega OT. Risk of glycemic disorder in elderly women adjusted by anthropometric parameters and cytokine genotypes. Rev Assoc Med Bras. 2011;57:565–569. doi: 10.1590/s0104-42302011000500016. [DOI] [PubMed] [Google Scholar]
  • 128.Yamashina M, Kaneko Y, Maesawa C, Kajiwara T, Ishii M, Fujiwara F, Taneichi H, Takebe N, Ishida W, Takahashi K, et al. Association of TNF-alpha gene promoter C-857T polymorphism with higher serum LDL cholesterol levels and carotid plaque formation in Japanese patients with type 2 diabetes. Tohoku J Exp Med. 2007;211:251–258. doi: 10.1620/tjem.211.251. [DOI] [PubMed] [Google Scholar]
  • 129.Feng RN, Zhao C, Sun CH, Li Y. Meta-analysis of TNF 308 G/A polymorphism and type 2 diabetes mellitus. PLoS One. 2011;6:e18480. doi: 10.1371/journal.pone.0018480. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 130.Vourvouhaki E, Carvalho CS. A Bayesian approach to the probability of coronary heart disease subject to the -308 tumor necrosis factor-α SNP. Biosystems. 2011;105:181–189. doi: 10.1016/j.biosystems.2011.03.010. [DOI] [PubMed] [Google Scholar]
  • 131.Szabó GV, Acsády G. Tumornecrosis-factor-α 308 GA polymorphism in atherosclerotic patients. Pathol Oncol Res. 2011;17:853–857. doi: 10.1007/s12253-011-9393-8. [DOI] [PubMed] [Google Scholar]
  • 132.Boraska V, Rayner NW, Groves CJ, Frayling TM, Diakite M, Rockett KA, Kwiatkowski DP, Day-Williams AG, McCarthy MI, Zeggini E. Large-scale association analysis of TNF/LTA gene region polymorphisms in type 2 diabetes. BMC Med Genet. 2010;11:69. doi: 10.1186/1471-2350-11-69. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 133.Jermendy A, Körner A, Kovács M, Madácsy L, Cseh K. PPAR-gamma2 pro12Ala polymorphism is associated with post-challenge abnormalities of glucose homeostasis in children and adolescents with obesity. J Pediatr Endocrinol Metab. 2011;24:55–59. doi: 10.1515/jpem.2011.111. [DOI] [PubMed] [Google Scholar]
  • 134.Ohara M, Maesawa C, Takebe N, Takahashi T, Yamashina M, Ono M, Matsui M, Sasai T, Honma H, Nagasawa K, et al. Different susceptibility to insulin resistance and fatty liver depending on the combination of TNF-α C-857T and adiponectin G+276T gene polymorphisms in Japanese subjects with type 2 diabetes. Tohoku J Exp Med. 2012;226:161–169. doi: 10.1620/tjem.226.161. [DOI] [PubMed] [Google Scholar]
  • 135.Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 2000;148:209–214. doi: 10.1016/s0021-9150(99)00463-3. [DOI] [PubMed] [Google Scholar]
  • 136.Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes. 2004;53:693–700. doi: 10.2337/diabetes.53.3.693. [DOI] [PubMed] [Google Scholar]
  • 137.Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004;27:813–823. doi: 10.2337/diacare.27.3.813. [DOI] [PubMed] [Google Scholar]
  • 138.Gimeno RE, Klaman LD. Adipose tissue as an active endocrine organ: recent advances. Curr Opin Pharmacol. 2005;5:122–128. doi: 10.1016/j.coph.2005.01.006. [DOI] [PubMed] [Google Scholar]
  • 139.Lazar MA. How obesity causes diabetes: not a tall tale. Science. 2005;307:373–375. doi: 10.1126/science.1104342. [DOI] [PubMed] [Google Scholar]
  • 140.Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005;115:1111–1119. doi: 10.1172/JCI25102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 141.Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem. 1995;270:26746–26749. doi: 10.1074/jbc.270.45.26746. [DOI] [PubMed] [Google Scholar]
  • 142.Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26:439–451. doi: 10.1210/er.2005-0005. [DOI] [PubMed] [Google Scholar]
  • 143.Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116:1784–1792. doi: 10.1172/JCI29126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 144.Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999;100:2473–2476. doi: 10.1161/01.cir.100.25.2473. [DOI] [PubMed] [Google Scholar]
  • 145.Kim JY, van de Wall E, Laplante M, Azzara A, Trujillo ME, Hofmann SM, Schraw T, Durand JL, Li H, Li G, et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest. 2007;117:2621–2637. doi: 10.1172/JCI31021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 146.Mohammadzadeh G, Zarghami N. Associations between single-nucleotide polymorphisms of the adiponectin gene, serum adiponectin levels and increased risk of type 2 diabetes mellitus in Iranian obese individuals. Scand J Clin Lab Invest. 2009;69:764–771. doi: 10.3109/00365510903137237. [DOI] [PubMed] [Google Scholar]
  • 147.Low CF, Mohd Tohit ER, Chong PP, Idris F. Adiponectin SNP45TG is associated with gestational diabetes mellitus. Arch Gynecol Obstet. 2011;283:1255–1260. doi: 10.1007/s00404-010-1548-4. [DOI] [PubMed] [Google Scholar]
  • 148.Melistas L, Mantzoros CS, Kontogianni M, Antonopoulou S, Ordovas JM, Yiannakouris N. Association of the +45T& gt; G and +276G& gt; T polymorphisms in the adiponectin gene with insulin resistance in nondiabetic Greek women. Eur J Endocrinol. 2009;161:845–852. doi: 10.1530/EJE-09-0492. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 149.Wang ZL, Xia B, Shrestha U, Jiang L, Ma CW, Chen Q, Chen H, Hu ZG. Correlation between adiponectin polymorphisms and non-alcoholic fatty liver disease with or without metabolic syndrome in Chinese population. J Endocrinol Invest. 2008;31:1086–1091. doi: 10.1007/BF03345657. [DOI] [PubMed] [Google Scholar]
  • 150.Hara K, Boutin P, Mori Y, Tobe K, Dina C, Yasuda K, Yamauchi T, Otabe S, Okada T, Eto K, et al. Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes. 2002;51:536–540. doi: 10.2337/diabetes.51.2.536. [DOI] [PubMed] [Google Scholar]
  • 151.Li LL, Kang XL, Ran XJ, Wang Y, Wang CH, Huang L, Ren J, Luo X, Mao XM. Associations between 45T/G polymorphism of the adiponectin gene and plasma adiponectin levels with type 2 diabetes. Clin Exp Pharmacol Physiol. 2007;34:1287–1290. doi: 10.1111/j.1440-1681.2007.04713.x. [DOI] [PubMed] [Google Scholar]
  • 152.Ruchat SM, Loos RJ, Rankinen T, Vohl MC, Weisnagel SJ, Després JP, Bouchard C, Pérusse L. Associations between glucose tolerance, insulin sensitivity and insulin secretion phenotypes and polymorphisms in adiponectin and adiponectin receptor genes in the Quebec Family Study. Diabet Med. 2008;25:400–406. doi: 10.1111/j.1464-5491.2008.02396.x. [DOI] [PubMed] [Google Scholar]
  • 153.Sutton BS, Weinert S, Langefeld CD, Williams AH, Campbell JK, Saad MF, Haffner SM, Norris JM, Bowden DW. Genetic analysis of adiponectin and obesity in Hispanic families: the IRAS Family Study. Hum Genet. 2005;117:107–118. doi: 10.1007/s00439-005-1260-9. [DOI] [PubMed] [Google Scholar]
  • 154.Mackevics V, Heid IM, Wagner SA, Cip P, Doppelmayr H, Lejnieks A, Gohlke H, Ladurner G, Illig T, Iglseder B, et al. The adiponectin gene is associated with adiponectin levels but not with characteristics of the insulin resistance syndrome in healthy Caucasians. Eur J Hum Genet. 2006;14:349–356. doi: 10.1038/sj.ejhg.5201552. [DOI] [PubMed] [Google Scholar]
  • 155.Lee SH, Lee TW, Ihm CG, Kim MJ, Woo JT, Chung JH. Genetics of diabetic nephropathy in type 2 DM: candidate gene analysis for the pathogenic role of inflammation. Nephrology (Carlton) 2005;10 Suppl:S32–S36. doi: 10.1111/j.1440-1797.2005.00454.x. [DOI] [PubMed] [Google Scholar]
  • 156.González-Sánchez JL, Zabena CA, Martínez-Larrad MT, Fernández-Pérez C, Pérez-Barba M, Laakso M, Serrano-Ríos M. An SNP in the adiponectin gene is associated with decreased serum adiponectin levels and risk for impaired glucose tolerance. Obes Res. 2005;13:807–812. doi: 10.1038/oby.2005.91. [DOI] [PubMed] [Google Scholar]
  • 157.Zacharova J, Chiasson JL, Laakso M. The common polymorphisms (single nucleotide polymorphism [SNP] +45 and SNP +276) of the adiponectin gene predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. Diabetes. 2005;54:893–899. doi: 10.2337/diabetes.54.3.893. [DOI] [PubMed] [Google Scholar]
  • 158.Nakatani K, Noma K, Nishioka J, Kasai Y, Morioka K, Katsuki A, Hori Y, Yano Y, Sumida Y, Wada H, et al. Adiponectin gene variation associates with the increasing risk of type 2 diabetes in non-diabetic Japanese subjects. Int J Mol Med. 2005;15:173–177. [PubMed] [Google Scholar]
  • 159.Ukkola O, Ravussin E, Jacobson P, Sjöström L, Bouchard C. Mutations in the adiponectin gene in lean and obese subjects from the Swedish obese subjects cohort. Metabolism. 2003;52:881–884. doi: 10.1016/s0026-0495(03)00074-x. [DOI] [PubMed] [Google Scholar]
  • 160.Menzaghi C, Ercolino T, Salvemini L, Coco A, Kim SH, Fini G, Doria A, Trischitta V. Multigenic control of serum adiponectin levels: evidence for a role of the APM1 gene and a locus on 14q13. Physiol Genomics. 2004;19:170–174. doi: 10.1152/physiolgenomics.00122.2004. [DOI] [PubMed] [Google Scholar]
  • 161.Bacci S, Menzaghi C, Ercolino T, Ma X, Rauseo A, Salvemini L, Vigna C, Fanelli R, Di Mario U, Doria A, et al. The +276 G/T single nucleotide polymorphism of the adiponectin gene is associated with coronary artery disease in type 2 diabetic patients. Diabetes Care. 2004;27:2015–2020. doi: 10.2337/diacare.27.8.2015. [DOI] [PubMed] [Google Scholar]
  • 162.Vozarova de Courten B, Hanson RL, Funahashi T, Lindsay RS, Matsuzawa Y, Tanaka S, Thameem F, Gruber JD, Froguel P, Wolford JK. Common Polymorphisms in the Adiponectin Gene ACDC Are Not Associated With Diabetes in Pima Indians. Diabetes. 2005;54:284–289. doi: 10.2337/diabetes.54.1.284. [DOI] [PubMed] [Google Scholar]
  • 163.Lacquemant C, Froguel P, Lobbens S, Izzo P, Dina C, Ruiz J. The adiponectin gene SNP+45 is associated with coronary artery disease in Type 2 (non-insulin-dependent) diabetes mellitus. Diabet Med. 2004;21:776–781. doi: 10.1111/j.1464-5491.2004.01224.x. [DOI] [PubMed] [Google Scholar]
  • 164.Vasseur F, Helbecque N, Dina C, Lobbens S, Delannoy V, Gaget S, Boutin P, Vaxillaire M, Leprêtre F, Dupont S, et al. Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. Hum Mol Genet. 2002;11:2607–2614. doi: 10.1093/hmg/11.21.2607. [DOI] [PubMed] [Google Scholar]
  • 165.Vimaleswaran KS, Radha V, Ramya K, Babu HN, Savitha N, Roopa V, Monalisa D, Deepa R, Ghosh S, Majumder PP, et al. A novel association of a polymorphism in the first intron of adiponectin gene with type 2 diabetes, obesity and hypoadiponectinemia in Asian Indians. Hum Genet. 2008;123:599–605. doi: 10.1007/s00439-008-0506-8. [DOI] [PubMed] [Google Scholar]

Articles from World Journal of Diabetes are provided here courtesy of Baishideng Publishing Group Inc

RESOURCES